Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Prostate Cancer Risk Stratification: Utilizing IsoPSA with mpMRI
November 20, 2025 | 3:30 p.m. ET
Join Urologic Oncologist Dr. Tarik Benidir for an in-depth presentation on how IsoPSA and mpMRI can complement each other to improve prostate biopsy decision making. This session will review clinical evidence on combining IsoPSA results with PI-RADS scoring, including the test’s utility for refining risk assessment in men with equivocal PI-RADS 3 results and identifying hidden MRI invisible csPCa lesions in PI-RADS 1 2 findings. Dr. Benidir will discuss the use of MRI with other ancillary tests, guideline-based patient selection, interpretation of IsoPSA results, and real-world cases. Dr. Benidir’s insights will educate clinicians on how to improve early detection of csPCa and enhancing the patient’s experience.
Meet the Speaker
Tarik Benidir, MD
Urologic Oncologist
Dr. Tarik Benidir is a clinical assistant professor and urologist that specializes in urologic cancer, providing surgical management to patients with localized or locally advanced prostate cancer. His research focuses on the optimization of patient selection for prostate focal therapy and the use of genomics, advanced imaging, and artificial intelligence to better treat prostate cancer patients.
This is a non-CME, company-led program developed and sponsored by IsoPSA, intended for healthcare professionals only. The content of this company-directed program is not sponsored or endorsed by the American Urological Association (AUA).